Article -> Article Details
Title | Pheochromocytoma Market Set for Rapid Growth by 2025 |
---|---|
Category | Fitness Health --> Addictions |
Meta Keywords | Pheochromocytoma Market |
Owner | vinit |
Description | |
Market Highlights According to MRFR analysis, Pheochromocytoma
Market is expected to register a CAGR of 3.84% during
the forecast period of 2019 to 2025. The global market was valued
at USD 2,814.75 Million in 2018. Pheochromocytoma is a catecholamine-secreting rare type of
adrenal gland tumor. In this condition, the adrenal gland produces excess
amounts of norepinephrine and epinephrine hormones, hence elevating the blood
pressure and heart rate. The global pheochromocytoma market is growing owing to the
increasing investment by major companies to develop specific treatment options,
high prevalence of pheochromocytoma, and an increasing number of clinical
trials for drugs for pheochromocytoma. Furthermore, the rapidly changing
lifestyle, rising healthcare expenditure, and increasing incidence rate of rare
tumors are also expected to fuel the market growth. However, the stringent
government regulations, lack of availability of specific drugs and lack of
awareness regarding the disease are expected to restrain the growth of the
global pheochromocytoma market. Several market players currently dominate the global
pheochromocytoma market. The key players are involved in product launches and
acquisitions to strengthen their market positions. Regional Analysis The market has been divided, by region, into the Americas,
Europe, Asia-Pacific, and the Middle East & Africa. The Americas is
expected to be the largest market owing to the increasing prevalence of
pheochromocytoma. The pheochromocytoma market in the Americas has further been
branched into North America and Latin America, with the North American market
divided into the US and Canada. The European pheochromocytoma market has been
categorized as Western Europe and Eastern Europe. The Western European market
has further been classified as Germany, France, the UK, Italy, Spain, and the
rest of Western Europe. The pheochromocytoma market in Asia-Pacific has been segmented
into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.
Due to the increasing patient pool suffering from rare tumors, the market in
Asia-Pacific is expected to be the fastest-growing. The pheochromocytoma market
in the Middle East & Africa has been divided into the Middle East and
Africa. Segmentation The Global Pheochromocytoma Market has been segmented based
on treatment type and end-user. The global pheochromocytoma market has been segmented, on
the basis of treatment type, into alpha-blockers, beta-blockers, surgery,
radionuclide treatment, and others. The surgery segment is expected to hold the
largest market share as it is the most preferred treatment option for
pheochromocytoma. The radionuclide treatment is expected to grow at the fastest
CAGR owing to an increasing number of applications of radiopharmaceuticals in
the treatment of various diseases. The market based on end-user has been segmented
into hospitals & clinics, research & academic institutes, and others.
Hospitals and clinics are the first point of treatment for any disease; hence
it is expected to hold the largest market share. Research & academic
institutes are expected to grow at the fastest CAGR owing to increasing
research & development activities for better treatment options for
pheochromocytoma. Key Players Some of the key players in the Global Pheochromocytoma
Market are Pfizer Inc. (US), Teva Pharmaceutical Company Limited
(Israel), Zydus Cadila (India), Novartis AG (Switzerland), Curium Pharma (UK),
Jubilant Cadista (US), AstraZeneca (UK), Mylan N.V. (US), Apotex Inc. (Canada),
Dr. Reddy’s Laboratories Ltd (India), Lupin (India), and Glenmark
Pharmaceuticals Limited (India). Other prominent players in the market include Exelixis,
Inc. (US), Progenics Pharmaceuticals, Inc. (US), Oncoceutics, Inc. (US), FUJIFILM
Holdings Corporation (Japan), and Advanced Accelerator Applications (France). |